← SynDRA

NERATINIB

SynDRA canonical compound SYN0005562 — structure-anchored drug synonym record

All known targets

• ERBB2
• EGFR
• KDR
• ERBB4
• ABL1
• SIK2
• RPS6KA2
• RPS6KA1
• PTK2B
• PTK2
• PRKD3
• PRKD2

Mechanisms of action (all sources)

• EGFR INHIBITOR
• Epidermal growth factor receptor erbB1 inhibitor
• ERBB2 INHIBITOR
• Receptor protein-tyrosine kinase erbB-2 inhibitor
• ERBB4 INHIBITOR
• Receptor protein-tyrosine kinase erbB-4 inhibitor
• KDR INHIBITOR
• ERBB2 ANTAGONIST
• EGFR ANTAGONIST

Drug classes

• Kinase Inhibitors
• Kinase Inhibitor
• P-Glycoprotein Inhibitors
• Tyrosine Kinase Inhibitors

ATC classes

• L01E · PROTEIN KINASE INHIBITORS

Cross-references

• PubChem CID: 9915743
• ChEMBL: CHEMBL180022
• DrugBank: DB11828
• ChEBI: CHEBI:61397
• KEGG: D08950
• RxNorm: 1940643
• Wikipedia: Neratinib
• TTD: D0Q9CY

Synonyms

• neratinib maleate
• HKI-272
• nerlynx
• CDP-820
• WAY-179272
• Neratinib (ERBB2 inhibitor)
• NERATINIB MALEATE
• UNII-9RM7XY23ZS
• 9RM7XY23ZS
• Neratinib maleate [MI]
• hki-272 maleate
• Nerlynx (TN)
• SCHEMBL2180998
• MolPort-044-561-003
• AKOS030524209
• DS-19892
• HKI 272
• Neratinib (HKI-272)
• Nerlynx
• PB 272
• JJH94R3PWB
• (2E)-N-[4-[[3-chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide
• CHEMBL180022
• 698387-09-6 (free base)
• HKI272
• (2E)-N-(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide
• (E)-N-(4-((3-Chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide
• N-(4-(3-Chloro-4-(2-pyridinylmethoxy)anilino)-3-cyano-7-ethoxy-6-quinolyl)-4-(dimethylamino)-2-butenamide
• (2e)-n-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide
• 2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-
• Neratinib [USAN]
• Neratinib(HKI-272)
• (E)-N-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide
• Neratinib [USAN:INN]
• UNII-JJH94R3PWB
• Neratinib- Bio-X
• (2E)-N-[4-({3-chloro-4-[(pyridin-2-yl)methoxy]phenyl}amino)-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide
• (E)-N-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide

Reported adverse events

• Epistaxis
• Fatigue
• Hepatotoxicity
• Muscle spasms
• Nail disorder
• Rash
• Weight decreased
• Decreased appetite
• Abdominal distension
• Alanine aminotransferase increased
• Dehydration
• Urinary tract infection